Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Dexmedetomidine Versus Oral Midazolam Premedication for Postoperative Negative Behavior Changes in Children
NCT06417125Phase 4Completed
- Sponsor
- Fujian Provincial Hospital
- Start
- May 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dexmedetomidine in Postoperative behavioral changes, emergence delirium (ED) and preoperative anxiety (3 arms), sponsored by Fujian Provincial Hospital. Primary endpoint: Incidence of postoperative negative behavior changes at 7 days. Started May 2024; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
Postoperative behavioral changesemergence delirium (ED)preoperative anxiety
Beyond the preview
Go deeper on NCT06417125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06417125.